Investors
A MESSAGE FROM OUR CEO
“We remain optimistic about the prospects of resomelagon in RA and other inflammatory diseases where significant populations of patients are underserved by existing therapies.”
-
November 22, 2023 RegulatoryNomination Committee appointed ahead of AGM 2024 in SynAct Pharma AB
-
November 14, 2023 Non RegulatorySynAct Pharma comments on ownership changes in Bioinvest Aps
SynAct Pharma published the Q3 2023 interim report on October 24, 2023.